Beliefs about medicines and adherence in women with breast cancer on adjuvant endocrine therapy

The Beliefs about Medicines Questionnaire (BMQ) and Adherence Starts with Knowledge (ASK-12) questionnaire were originally developed and validated in Western populations to assess beliefs and barriers to medication adherence. The study aim is to validate the BMQ and ASK-12 questionnaire for use in a Singapore population with early stage breast cancer. English-speaking women on adjuvant endocrine therapy ( n = 157) were recruited. The BMQ-Specific showed good internal consistency with structural validity. The internal consistency of BMQ-General and ASK-12 Behaviour scale improved with the new factor structure obtained from exploratory factor analysis. Further studies are needed to confirm these factor structures.

Download Full-text

Information needs of post-menopausal women with hormone receptor positive early-stage breast cancer considering adjuvant endocrine therapy

Patient Education and Counseling ◽

10.1016/j.pec.2013.03.019 ◽

2013 ◽

Vol 93 (1) ◽

pp. 114-121 ◽

Cited By ~ 5

Author(s):

Deb Feldman-Stewart ◽

Yolanda Madarnas ◽

Mihaela Mates ◽

Christine Tong ◽

Eva Grunfeld ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Information Needs ◽

Early Stage ◽

Adjuvant Endocrine Therapy ◽

Early Stage Breast Cancer ◽

Hormone Receptor Positive ◽

Menopausal Women ◽

Post Menopausal

Download Full-text

Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer

Psycho-Oncology ◽

10.1002/pon.4771 ◽

2018 ◽

Vol 27 (9) ◽

pp. 2096-2103 ◽

Cited By ~ 5

Author(s):

Arden L. Corter ◽

Reuben Broom ◽

David Porter ◽

Vernon Harvey ◽

Michael Findlay

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Early Stage ◽

Adjuvant Endocrine Therapy ◽

Early Stage Breast Cancer

Download Full-text

Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05715-1 ◽

2020 ◽

Vol 182 (2) ◽

pp. 259-266

Author(s):

Daniel Reinhorn ◽

Rinat Yerushalmi ◽

Assaf Moore ◽

Alexandra Desnoyers ◽

Ramy R. Saleh ◽

...

Keyword(s):

Breast Cancer ◽

Adverse Events ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Early Stage ◽

Adjuvant Endocrine Therapy ◽

Early Stage Breast Cancer

Download Full-text

Abstract OT3-05-05: MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2- breast cancer

10.1158/1538-7445.sabcs17-ot3-05-05 ◽

2018 ◽

Author(s):

P Rastogi ◽

M Toi ◽

N Harbeck ◽

N Bourayou ◽

M Frenzel ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Endocrine Therapy ◽

Early Stage ◽

Adjuvant Endocrine Therapy ◽

Open Label ◽

Phase 3 ◽

Node Positive ◽

Her2 Breast Cancer ◽

Open Label Phase

Download Full-text

Patterns of relapse in older women diagnosed with estrogen receptor (ER)–positive early-stage breast cancer (BC) treated with lumpectomy without adjuvant endocrine therapy (ET)

Journal of Radiation Oncology ◽

10.1007/s13566-019-00405-y ◽

2019 ◽

Vol 8 (3) ◽

pp. 349-353

Author(s):

Manjeet Chadha ◽

T. Shao ◽

S. Cate ◽

S. Malamud ◽

C. White ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Older Women ◽

Endocrine Therapy ◽

Early Stage ◽

Adjuvant Endocrine Therapy ◽

Early Stage Breast Cancer ◽

Er Positive

Download Full-text

Controversies in Adjuvant Endocrine Therapy for Breast Cancer

American Society of Clinical Oncology Educational Book ◽

10.14694/edbook_am.2012.32.87 ◽

2012 ◽

pp. 20-26

Author(s):

Stephen R. Johnston

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Aromatase Inhibitors ◽

Early Stage ◽

Premenopausal Women ◽

Adjuvant Endocrine Therapy ◽

Risk Of Recurrence ◽

Er Positive ◽

Added Benefit ◽

Positive Breast Cancer

Overview: Adjuvant endocrine therapy for early-stage breast cancer has had the single biggest impact on improving survival from the disease—with tamoxifen alone contributing to saving many thousands of lives. In postmenopausal women, additional progress has been made by the incorporation of aromatase inhibitors into the treatment of early-stage, estrogen receptor (ER)–positive breast cancer, as several large well-conducted trials have established either “up-front” or “switch” strategies that are now widely used. To date, both have been shown to be beneficial when compared with tamoxifen alone, although controversy exists as to which approach is superior. Increasingly, extended adjuvant therapy is being considered, as “longer may be better” for some women who have an ongoing risk of recurrence beyond 5 years. However, controversy remains as to how long adjuvant endocrine therapy should be given for; in clinical practice, clinicians balance the level of risk for individual patients versus any ongoing toxicity concerns. For premenopausal women, with ER-positive breast cancer, tamoxifen remains the gold standard with uncertainty in the added overall benefit of ovarian suppression. Important clinical trials have recently been completed that may help answers this question, including whether complete estrogen deprivation using a luteinizing hormone releasing hormone (LHRH) agonist plus aromatase inhibitors (AIs) is of added benefit. In recent years, molecular profiling of ER-positive breast cancer has started to distinguish those women with a low risk of recurrence on endocrine therapy who may not need chemotherapy. Thus, with more therapy options and greater tumour stratification, modern, adjuvant endocrine therapy is becoming increasingly personalised to suit each individual patient's risk.

Download Full-text